Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Immune Signature Predicts Poor Outcome in Influenza Patients

By LabMedica International staff writers
Posted on 27 Feb 2014
A signature immune response has been identified that might help doctors identify which newly diagnosed influenza patients are most likely to develop severe symptoms and suffer poor outcomes.

Children are an at-risk population for developing complications following influenza infection, but immunologic correlates of disease severity are not understood and it has been hypothesized that innate cellular immune responses at the site of infection would correlate with disease outcome.

Scientists at St. More...
Jude Children’s Research Hospital (Memphis, TN, USA) conducted an observational cohort study with longitudinal sampling of peripheral and mucosal sites in 84 naturally influenza-infected individuals, including infants. Cellular responses, viral loads, and cytokines were quantified from nasal lavages and blood, and correlated to clinical severity. Sampling began when patients sought medical attention for influenza symptoms, and was repeated on days 3, 7, 10, and 28. Along with measuring levels of influenza virus in the nose and sinuses, researchers measured 42 cytokines and antibodies against circulating influenza viruses.

The testing showed children and adults were equally successful at eliminating the virus regardless of the subtype. In fact, based on cytokine levels in the blood, nose, and sinuses of patients, children mounted a more aggressive inflammatory response than adults. Adjusting for age and viral load, an innate immune profile characterized by increased nasal lavage monocyte chemotactic protein-3, interferon (IFN)-α2, and plasma interleukin 10 (IL-10) levels at enrollment predicted progression to severe disease. Increased plasma IL-10, monocyte chemotactic protein-3, and IL-6 levels predicted hospitalization.

Christine Oshansky, PhD, the senior author said, “The fact that the innate immune response was stronger in the airways of children than adults was a surprise. Previous studies using different measures reported that children mounted a weaker immune response. In this study, the hyperactive immune response diminished with age, but it may help explain why toddlers and infants are more likely to develop severe symptoms. Normal genetic variation might play a role in the innate immune response.” The study was published on February 15, 2014, in the American Journal of Respiratory and Critical Care Medicine.

Related Links:

St. Jude Children’s Research Hospital



New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.